Astellas Pharma Global Development, Inc. Drug Pipeline

Astellas Pharma Global Development, Inc. maintains a substantial clinical development portfolio, with 28 active trials out of 181 total trials registered since 2008. The pipeline spans multiple phases, including 13 Phase 1, 10 Phase 2, 8 Phase 3, and 1 Phase 4 trials. Activity is spread across 10 therapeutic areas, although a significant concentration exists within Oncology, which accounts for 29 active trials, representing 104% of active programs. Within Oncology, the leading indications are Solid Tumor (Advanced) with 8 active trials (3 in Phase 3), Pancreatic Cancer with 6 active trials (1 in Phase 3), Gastric Cancer with 5 active trials (3 in Phase 3), Prostate Cancer with 4 active trials, and Bladder Cancer with 3 active trials (1 in Phase 3). Other therapeutic areas with active trials include Women's Health, Renal, Immunology, CNS, and Urology, each with a smaller number of ongoing studies. The notable weighting toward Phase 3 trials in key Oncology indications suggests a focus on near-term clinical catalysts within this therapeutic area.